RI 624

DB05892ExperimentalProtein Based Therapies

RI 624 is a novel humanized monoclonal antibody that blocks nerve growth factor (NGF), a key mediator of acute and chronic pain. RI 624 is being developed by Rinat and... RI 624 is being developed by Rinat and is currently in Phase I clinical trials.

Mechanism
Curator reviewed
Primary indication
Investigated for use/treatment in pain (acute or chronic).Curator reviewed
Code names
RI 624

Resolves to

Targets

What you can answer from here — as of April 02, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
382Drug interactionsStructured to mechanism, not free text
Sign in

Which drugs share a target with RI 624, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.

Create Account